Cargando…
Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue
BACKGROUND: Tenosynovial giant cell tumor (TSGCT) is a benign fibrohistiocytic tumor that affects the synovium of joints, bursa, and tendon sheaths and is categorized into localized TSGCT (LTSGCT) and diffuse TSGCT (DTSGCT). LTSGCT and DTSGCT are characterized by recurrent fusions involving the colo...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623913/ https://www.ncbi.nlm.nih.gov/pubmed/36320082 http://dx.doi.org/10.1186/s13000-022-01266-9 |
_version_ | 1784822112348798976 |
---|---|
author | Sugita, Shintaro Takenami, Tomoko Kido, Tomomi Aoyama, Tomoyuki Hosaka, Michiko Segawa, Keiko Sugawara, Taro Fujita, Hiromi Shimizu, Junya Murahashi, Yasutaka Emori, Makoto Hasegawa, Tadashi |
author_facet | Sugita, Shintaro Takenami, Tomoko Kido, Tomomi Aoyama, Tomoyuki Hosaka, Michiko Segawa, Keiko Sugawara, Taro Fujita, Hiromi Shimizu, Junya Murahashi, Yasutaka Emori, Makoto Hasegawa, Tadashi |
author_sort | Sugita, Shintaro |
collection | PubMed |
description | BACKGROUND: Tenosynovial giant cell tumor (TSGCT) is a benign fibrohistiocytic tumor that affects the synovium of joints, bursa, and tendon sheaths and is categorized into localized TSGCT (LTSGCT) and diffuse TSGCT (DTSGCT). LTSGCT and DTSGCT are characterized by recurrent fusions involving the colony-stimulating factor 1 (CSF1) gene and its translocation partner collagen type VI alpha 3 chain. The fusion gene induces intratumoral overexpression of CSF1 mRNA and CSF1 protein. CSF1 expression is a characteristic finding of TSGCT and detection of CSF1 mRNA and CSF1 protein may be useful for the pathological diagnosis. Although there have been no effective anti-CSF1 antibodies to date, in situ hybridization (ISH) for CSF1 mRNA has been performed to detect CSF1 expression in TSGCT. We performed CSF1 immunohistochemistry (IHC) using anti-CSF1 antibody (clone 2D10) in cases of TSGCT, giant cell-rich tumor (GCRT), and GCRT-like lesion and verified its utility for the pathological diagnosis of TSGCT. METHODS: We performed CSF1 IHC in 110 cases including 44 LTSGCTs, 20 DTSGCTs, 1 malignant TSGCT (MTSGCT), 10 giant cell tumors of bone, 2 giant cell reparative granulomas, 3 aneurysmal bone cysts, 10 undifferentiated pleomorphic sarcomas, 10 leiomyosarcomas, and 10 myxofibrosarcomas. We performed fluorescence ISH (FISH) for CSF1 rearrangement to confirm CSF1 expression on IHC in TSGCTs. We considered the specimens to have CSF1 rearrangement if a split signal was observed in greater than 2% of the tumor cells. RESULTS: Overall, 50 of 65 TSGCT cases, including 35 of the 44 LTSGCTs and 15 of the 20 DTSGCTs, showed distinct scattered expression of CSF1 in the majority of mononuclear tumor cells. MTSGCT showed no CSF1 expression. Non-TSGCT cases were negative for CSF1. FISH revealed CSF1 rearrangement in 6 of 7 CSF1-positive cases on IHC. On the other hand, FISH detected no CSF1 rearrangement in all CSF1-negative cases on IHC. Thus, the results of IHC corresponded to those of FISH. CONCLUSION: We revealed characteristic CSF1 expression on IHC in cases of TSGCT, whereas the cases of non-TSGCT exhibited no CSF1 expression. CSF1 IHC may be useful for differentiating TSGCTs from histologically mimicking GCRTs and GCRT-like lesions. |
format | Online Article Text |
id | pubmed-9623913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96239132022-11-02 Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue Sugita, Shintaro Takenami, Tomoko Kido, Tomomi Aoyama, Tomoyuki Hosaka, Michiko Segawa, Keiko Sugawara, Taro Fujita, Hiromi Shimizu, Junya Murahashi, Yasutaka Emori, Makoto Hasegawa, Tadashi Diagn Pathol Research BACKGROUND: Tenosynovial giant cell tumor (TSGCT) is a benign fibrohistiocytic tumor that affects the synovium of joints, bursa, and tendon sheaths and is categorized into localized TSGCT (LTSGCT) and diffuse TSGCT (DTSGCT). LTSGCT and DTSGCT are characterized by recurrent fusions involving the colony-stimulating factor 1 (CSF1) gene and its translocation partner collagen type VI alpha 3 chain. The fusion gene induces intratumoral overexpression of CSF1 mRNA and CSF1 protein. CSF1 expression is a characteristic finding of TSGCT and detection of CSF1 mRNA and CSF1 protein may be useful for the pathological diagnosis. Although there have been no effective anti-CSF1 antibodies to date, in situ hybridization (ISH) for CSF1 mRNA has been performed to detect CSF1 expression in TSGCT. We performed CSF1 immunohistochemistry (IHC) using anti-CSF1 antibody (clone 2D10) in cases of TSGCT, giant cell-rich tumor (GCRT), and GCRT-like lesion and verified its utility for the pathological diagnosis of TSGCT. METHODS: We performed CSF1 IHC in 110 cases including 44 LTSGCTs, 20 DTSGCTs, 1 malignant TSGCT (MTSGCT), 10 giant cell tumors of bone, 2 giant cell reparative granulomas, 3 aneurysmal bone cysts, 10 undifferentiated pleomorphic sarcomas, 10 leiomyosarcomas, and 10 myxofibrosarcomas. We performed fluorescence ISH (FISH) for CSF1 rearrangement to confirm CSF1 expression on IHC in TSGCTs. We considered the specimens to have CSF1 rearrangement if a split signal was observed in greater than 2% of the tumor cells. RESULTS: Overall, 50 of 65 TSGCT cases, including 35 of the 44 LTSGCTs and 15 of the 20 DTSGCTs, showed distinct scattered expression of CSF1 in the majority of mononuclear tumor cells. MTSGCT showed no CSF1 expression. Non-TSGCT cases were negative for CSF1. FISH revealed CSF1 rearrangement in 6 of 7 CSF1-positive cases on IHC. On the other hand, FISH detected no CSF1 rearrangement in all CSF1-negative cases on IHC. Thus, the results of IHC corresponded to those of FISH. CONCLUSION: We revealed characteristic CSF1 expression on IHC in cases of TSGCT, whereas the cases of non-TSGCT exhibited no CSF1 expression. CSF1 IHC may be useful for differentiating TSGCTs from histologically mimicking GCRTs and GCRT-like lesions. BioMed Central 2022-11-01 /pmc/articles/PMC9623913/ /pubmed/36320082 http://dx.doi.org/10.1186/s13000-022-01266-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Sugita, Shintaro Takenami, Tomoko Kido, Tomomi Aoyama, Tomoyuki Hosaka, Michiko Segawa, Keiko Sugawara, Taro Fujita, Hiromi Shimizu, Junya Murahashi, Yasutaka Emori, Makoto Hasegawa, Tadashi Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title | Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title_full | Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title_fullStr | Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title_full_unstemmed | Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title_short | Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
title_sort | diagnostic utility of csf1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623913/ https://www.ncbi.nlm.nih.gov/pubmed/36320082 http://dx.doi.org/10.1186/s13000-022-01266-9 |
work_keys_str_mv | AT sugitashintaro diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT takenamitomoko diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT kidotomomi diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT aoyamatomoyuki diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT hosakamichiko diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT segawakeiko diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT sugawarataro diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT fujitahiromi diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT shimizujunya diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT murahashiyasutaka diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT emorimakoto diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue AT hasegawatadashi diagnosticutilityofcsf1immunohistochemistryintenosynovialgiantcelltumorfordifferentiatingfromgiantcellrichtumorsandtumorlikelesionsofboneandsofttissue |